FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4239416660> ?p ?o ?g. }

• W4239416660 endingPage "4584" @default.
• W4239416660 startingPage "4584" @default.
• W4239416660 abstract "Abstract Purpose: The combination of chemotherapy with the chimeric anti-CD20 antibody Rituximab has been reported to be highly active in the treatment of follicular lymphoma. The frequency and dosage of rituximab required to induce the maximum effect in follicular NHL is not defined. To evaluate how often rituximab should be added to standard chemotherapy to achieve maximum remission rates, we have initiated a prospective randomized multicenter phase II study. Methods: Patients (pts) with stage III/IV CD20 positive follicular NHL who were chemotherapy naïve were randomly assigned to receive 6 courses of a standard CHOP-21 chemotherapy, accompanied by rituximab 375 mg/m2 at day 0 only with the first CHOP course (arm A), with the first 3 CHOP courses (arm B) or with all 6 CHOP courses (Arm C). The major endpoint was the rate of molecular remission in bone marrow and peripheral blood in initially t(14;18)-positive pts, assessed by PCR. Other endpoints of the study were overall and complete response rates, toxicity rate and time to progression. Results: Since September 2000, 104 pts with a median age of 57 years (range 30–80) were recruited. 33 pts were randomized to arm A, 35 to arm B and 36 to arm C. So far 69 pts have been documented completely after all 6 cycles and are evaluable for side effects. All three treatment arms were well tolerated. The incidence of adverse events and Grade 4 toxicity was similar in all groups. One treatment related death was observed 2 months after completion of therapy due to hepatitis B. The overall response rate (ORR) of the whole group, which was evaluable in 69 pts so far, was 90 % (62 of 69 pts), with 20 complete and 42 partial remissions. Conclusion: This multicenter, randomized, phase II trial addresses for the first time the optimal frequency and dosage of rituximab infusions in the combined immuno-chemotherapy. In the first interim analysis of the ongoing trial, similar hematologic, gastrointestinal and infectious toxicity was observed in all treatment arms." @default.
• W4239416660 created "2022-05-12" @default.
• W4239416660 creator A5003987574 @default.
• W4239416660 creator A5005481013 @default.
• W4239416660 creator A5006107813 @default.
• W4239416660 creator A5006671688 @default.
• W4239416660 creator A5014476478 @default.
• W4239416660 creator A5024652430 @default.
• W4239416660 creator A5055698433 @default.
• W4239416660 creator A5057209685 @default.
• W4239416660 creator A5058796261 @default.
• W4239416660 creator A5063091259 @default.
• W4239416660 creator A5067574718 @default.
• W4239416660 creator A5067657650 @default.
• W4239416660 creator A5067812542 @default.
• W4239416660 creator A5074477435 @default.
• W4239416660 date "2004-11-16" @default.
• W4239416660 modified "2023-10-03" @default.
• W4239416660 title "How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Added to 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Non-Hodgkins Lymphoma (HD2000-Trial)." @default.
• W4239416660 doi "https://doi.org/10.1182/blood.v104.11.4584.4584" @default.
• W4239416660 hasPublicationYear "2004" @default.
• W4239416660 type Work @default.
• W4239416660 citedByCount "2" @default.
• W4239416660 countsByYear W42394166602012 @default.
• W4239416660 crossrefType "journal-article" @default.
• W4239416660 hasAuthorship W4239416660A5003987574 @default.
• W4239416660 hasAuthorship W4239416660A5005481013 @default.
• W4239416660 hasAuthorship W4239416660A5006107813 @default.
• W4239416660 hasAuthorship W4239416660A5006671688 @default.
• W4239416660 hasAuthorship W4239416660A5014476478 @default.
• W4239416660 hasAuthorship W4239416660A5024652430 @default.
• W4239416660 hasAuthorship W4239416660A5055698433 @default.
• W4239416660 hasAuthorship W4239416660A5057209685 @default.
• W4239416660 hasAuthorship W4239416660A5058796261 @default.
• W4239416660 hasAuthorship W4239416660A5063091259 @default.
• W4239416660 hasAuthorship W4239416660A5067574718 @default.
• W4239416660 hasAuthorship W4239416660A5067657650 @default.
• W4239416660 hasAuthorship W4239416660A5067812542 @default.
• W4239416660 hasAuthorship W4239416660A5074477435 @default.
• W4239416660 hasConcept C126322002 @default.
• W4239416660 hasConcept C141071460 @default.
• W4239416660 hasConcept C143998085 @default.
• W4239416660 hasConcept C168563851 @default.
• W4239416660 hasConcept C197934379 @default.
• W4239416660 hasConcept C203092338 @default.
• W4239416660 hasConcept C2776694085 @default.
• W4239416660 hasConcept C2777058707 @default.
• W4239416660 hasConcept C2778336483 @default.
• W4239416660 hasConcept C2779338263 @default.
• W4239416660 hasConcept C2779725641 @default.
• W4239416660 hasConcept C2780653079 @default.
• W4239416660 hasConcept C71924100 @default.
• W4239416660 hasConcept C90924648 @default.
• W4239416660 hasConceptScore W4239416660C126322002 @default.
• W4239416660 hasConceptScore W4239416660C141071460 @default.
• W4239416660 hasConceptScore W4239416660C143998085 @default.
• W4239416660 hasConceptScore W4239416660C168563851 @default.
• W4239416660 hasConceptScore W4239416660C197934379 @default.
• W4239416660 hasConceptScore W4239416660C203092338 @default.
• W4239416660 hasConceptScore W4239416660C2776694085 @default.
• W4239416660 hasConceptScore W4239416660C2777058707 @default.
• W4239416660 hasConceptScore W4239416660C2778336483 @default.
• W4239416660 hasConceptScore W4239416660C2779338263 @default.
• W4239416660 hasConceptScore W4239416660C2779725641 @default.
• W4239416660 hasConceptScore W4239416660C2780653079 @default.
• W4239416660 hasConceptScore W4239416660C71924100 @default.
• W4239416660 hasConceptScore W4239416660C90924648 @default.
• W4239416660 hasIssue "11" @default.
• W4239416660 hasLocation W42394166601 @default.
• W4239416660 hasOpenAccess W4239416660 @default.
• W4239416660 hasPrimaryLocation W42394166601 @default.
• W4239416660 hasRelatedWork W1970884884 @default.
• W4239416660 hasRelatedWork W2050334765 @default.
• W4239416660 hasRelatedWork W2186179458 @default.
• W4239416660 hasRelatedWork W2374533761 @default.
• W4239416660 hasRelatedWork W2408094891 @default.
• W4239416660 hasRelatedWork W2418195638 @default.
• W4239416660 hasRelatedWork W2562269384 @default.
• W4239416660 hasRelatedWork W2593931560 @default.
• W4239416660 hasRelatedWork W2980299611 @default.
• W4239416660 hasRelatedWork W2980321817 @default.
• W4239416660 hasVolume "104" @default.
• W4239416660 isParatext "false" @default.
• W4239416660 isRetracted "false" @default.
• W4239416660 workType "article" @default.